USRE29835E
(en)
|
1971-06-01 |
1978-11-14 |
Icn Pharmaceuticals |
1,2,4-Triazole nucleosides
|
US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
US3994974A
(en)
|
1972-02-05 |
1976-11-30 |
Yamanouchi Pharmaceutical Co., Ltd. |
α-Aminomethylbenzyl alcohol derivatives
|
US3852267A
(en)
|
1972-08-04 |
1974-12-03 |
Icn Pharmaceuticals |
Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
US5736155A
(en)
|
1984-08-08 |
1998-04-07 |
The Liposome Company, Inc. |
Encapsulation of antineoplastic agents in liposomes
|
US5077056A
(en)
|
1984-08-08 |
1991-12-31 |
The Liposome Company, Inc. |
Encapsulation of antineoplastic agents in liposomes
|
NL8403224A
(nl)
|
1984-10-24 |
1986-05-16 |
Oce Andeno Bv |
Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
|
US5223263A
(en)
|
1988-07-07 |
1993-06-29 |
Vical, Inc. |
Liponucleotide-containing liposomes
|
US4797285A
(en)
|
1985-12-06 |
1989-01-10 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
Lipsome/anthraquinone drug composition and method
|
US5154930A
(en)
|
1987-03-05 |
1992-10-13 |
The Liposome Company, Inc. |
Pharmacological agent-lipid solution preparation
|
GB8719367D0
(en)
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
IL91664A
(en)
|
1988-09-28 |
1993-05-13 |
Yissum Res Dev Co |
Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
|
US6132763A
(en)
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
US5705363A
(en)
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5077057A
(en)
|
1989-04-05 |
1991-12-31 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5277914A
(en)
|
1989-03-31 |
1994-01-11 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5194654A
(en)
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5411947A
(en)
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5463092A
(en)
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
JPH05506230A
(ja)
|
1990-04-06 |
1993-09-16 |
ジーンラブス テクノロジイズ インコーポレイテッド |
C型肝炎ウイルスエピトープ
|
US5091188A
(en)
|
1990-04-26 |
1992-02-25 |
Haynes Duncan H |
Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
|
US6060080A
(en)
|
1990-07-16 |
2000-05-09 |
Daiichi Pharmaceutical Co., Ltd. |
Liposomal products
|
JP2599492B2
(ja)
|
1990-08-21 |
1997-04-09 |
第一製薬株式会社 |
リポソーム製剤の製造法
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5149794A
(en)
|
1990-11-01 |
1992-09-22 |
State Of Oregon |
Covalent lipid-drug conjugates for drug targeting
|
US5543389A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5256641A
(en)
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5157027A
(en)
|
1991-05-13 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Bisphosphonate squalene synthetase inhibitors and method
|
NZ243567A
(en)
|
1991-07-22 |
1995-04-27 |
Bristol Myers Squibb Co |
Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
|
US5554728A
(en)
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
TW224053B
(pl)
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
DE4200821A1
(de)
|
1992-01-15 |
1993-07-22 |
Bayer Ag |
Geschmacksmaskierte pharmazeutische mittel
|
US5676942A
(en)
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5405598A
(en)
|
1992-02-24 |
1995-04-11 |
Schinazi; Raymond F. |
Sensitizing agents for use in boron neutron capture therapy
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US5426183A
(en)
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5256798A
(en)
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
BR9302427A
(pt)
|
1992-06-22 |
1994-01-11 |
Lilly Co Eli |
Processo estereo seletivo para a preparacao de um derivado de riboturanosila
|
CA2105112C
(en)
|
1992-09-01 |
2005-08-02 |
Thomas C. Britton |
A process for anomerizing nucleosides
|
GB9226729D0
(en)
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
WO1994019012A2
(en)
|
1993-02-24 |
1994-09-01 |
Wang Jui H |
Compositions and methods of application of reactive antiviral polymers
|
US6180134B1
(en)
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
EP0773029A4
(en)
|
1993-07-19 |
1997-09-03 |
Tokyo Tanabe Co |
HEPATITIS C VIRUS PROLIFERATION INHIBITOR
|
US7375198B2
(en)
|
1993-10-26 |
2008-05-20 |
Affymetrix, Inc. |
Modified nucleic acid probes
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
ES2174915T3
(es)
|
1993-11-10 |
2002-11-16 |
Enzon Inc |
Productos de conjugacion mejorados de un interferon con un polimero.
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
WO1995035102A1
(en)
|
1994-06-22 |
1995-12-28 |
Nexstar Pharmaceuticals, Inc. |
Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US6391859B1
(en)
|
1995-01-27 |
2002-05-21 |
Emory University |
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
|
US5703058A
(en)
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5767097A
(en)
|
1996-01-23 |
1998-06-16 |
Icn Pharmaceuticals, Inc. |
Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
|
GB9602028D0
(en)
|
1996-02-01 |
1996-04-03 |
Amersham Int Plc |
Nucleoside analogues
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
WO1997032018A2
(en)
|
1996-02-29 |
1997-09-04 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
GB9609932D0
(en)
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
US6214375B1
(en)
|
1996-07-16 |
2001-04-10 |
Generex Pharmaceuticals, Inc. |
Phospholipid formulations
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
TW520297B
(en)
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
US6455690B1
(en)
|
1996-10-16 |
2002-09-24 |
Robert Tam |
L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
|
DK1132393T3
(da)
|
1996-10-16 |
2003-07-21 |
Ribapharm Inc |
L-Ribavirin og anvendelser heraf
|
SI20024A
(sl)
|
1996-10-16 |
2000-02-29 |
Icn Pharmaceuticals, Inc. |
Purinovi L-nukleozidi, analogi in uporaba od teh
|
US6509320B1
(en)
|
1996-10-16 |
2003-01-21 |
Icn Pharmaceuticals, Inc. |
Purine L-nucleosides, analogs and uses thereof
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US5827533A
(en)
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
AU724974B2
(en)
|
1997-06-30 |
2000-10-05 |
Merz Pharma Gmbh & Co. Kgaa |
1-amino-alkylcyclohexane NMDA receptor antagonists
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
US6245750B1
(en)
|
1998-01-23 |
2001-06-12 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic agents
|
PT1058686E
(pt)
|
1998-02-25 |
2007-01-31 |
Raymond F Schinazi |
2'-fluoronucleósidos
|
US6787305B1
(en)
|
1998-03-13 |
2004-09-07 |
Invitrogen Corporation |
Compositions and methods for enhanced synthesis of nucleic acid molecules
|
WO1999049873A1
(en)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
US20010014352A1
(en)
|
1998-05-27 |
2001-08-16 |
Udit Batra |
Compressed tablet formulation
|
US6200598B1
(en)
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6726925B1
(en)
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
EP1122260B1
(en)
|
1998-10-16 |
2004-12-15 |
Mercian Corporation |
Crystallization of doxorubicin hydrochloride
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US7919119B2
(en)
|
1999-05-27 |
2011-04-05 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
CN1079473C
(zh)
|
1999-05-31 |
2002-02-20 |
李岭群 |
预制梁连接筋
|
WO2001005433A2
(en)
|
1999-07-14 |
2001-01-25 |
Board Of Regents, The University Of Texas System |
Delivery and retention of activity agents to lymph nodes
|
KR100789162B1
(ko)
|
1999-11-12 |
2007-12-28 |
파마셋 인코포레이티드 |
2'-데옥시-l-뉴클레오사이드의 합성
|
US20060034937A1
(en)
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
KR20080021797A
(ko)
|
2000-05-26 |
2008-03-07 |
이데닉스(케이만)리미티드 |
플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
|
FR2810322B1
(fr)
|
2000-06-14 |
2006-11-10 |
Pasteur Institut |
PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
UA72612C2
(en)
|
2000-07-06 |
2005-03-15 |
|
Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
|
DK1301519T4
(da)
|
2000-07-21 |
2021-12-20 |
Gilead Sciences Inc |
Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
|
US6897201B2
(en)
|
2000-08-21 |
2005-05-24 |
Inspire Pharmaceuticals, Inc. |
Compositions and methods for the treatment of glaucoma or ocular hypertension
|
AR039558A1
(es)
|
2000-08-21 |
2005-02-23 |
Inspire Pharmaceuticals Inc |
Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
|
US7018985B1
(en)
|
2000-08-21 |
2006-03-28 |
Inspire Pharmaceuticals, Inc. |
Composition and method for inhibiting platelet aggregation
|
US6555677B2
(en)
|
2000-10-31 |
2003-04-29 |
Merck & Co., Inc. |
Phase transfer catalyzed glycosidation of an indolocarbazole
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
MY134070A
(en)
|
2001-01-22 |
2007-11-30 |
Isis Pharmaceuticals Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
MY129350A
(en)
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
US6962991B2
(en)
|
2001-09-12 |
2005-11-08 |
Epoch Biosciences, Inc. |
Process for the synthesis of pyrazolopyrimidines
|
US7227019B2
(en)
|
2001-09-13 |
2007-06-05 |
Bristol-Myers Squibb Company |
Process for the preparation of rebeccamycin and analogs thereof
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
EP1448170A4
(en)
|
2001-11-27 |
2010-05-12 |
Bristol Myers Squibb Co |
EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
|
WO2003063771A2
(en)
|
2001-12-14 |
2003-08-07 |
Pharmasset Ltd. |
N4-acylcytosine nucleosides for treatment of viral iinfections
|
US20030153744A1
(en)
|
2001-12-21 |
2003-08-14 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza L-nucleosides
|
US7070801B2
(en)
|
2002-01-30 |
2006-07-04 |
National Institute Of Advanced Industrial Science And Technology |
Sugar-modified liposome and products comprising the liposome
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
EP1476169B1
(en)
|
2002-02-13 |
2013-03-20 |
Merck Sharp & Dohme Corp. |
Inhibiting orthopoxvirus replication with nucleoside compounds
|
JP2005525358A
(ja)
|
2002-02-28 |
2005-08-25 |
ビオタ インコーポレーティッド |
ヌクレオチド模倣体およびそのプロドラッグ
|
AU2003213628A1
(en)
|
2002-02-28 |
2003-09-16 |
Biota, Inc. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
JP2005523922A
(ja)
|
2002-04-26 |
2005-08-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
非ヌクレオシド逆転写酵素阻害剤
|
US20040014108A1
(en)
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
CN1671710A
(zh)
|
2002-06-04 |
2005-09-21 |
新创世纪药品公司 |
用作抗病毒药物的吡唑并[1,5-a]嘧啶化合物
|
US7906491B2
(en)
|
2002-06-07 |
2011-03-15 |
Univisitair Medisch Centrum Utrecht |
Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs)
|
CA2488484A1
(en)
|
2002-06-27 |
2004-01-08 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
PL374781A1
(pl)
|
2002-06-28 |
2005-10-31 |
Idenix (Cayman) Limited |
Ester 2'-C-metylo-3'-O-L-walinowy rybofuranozylocytydyny do leczenia zakażeń Flaviviridae
|
BR0305426A
(pt)
|
2002-07-01 |
2004-08-24 |
Upjohn Co |
Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
|
US20040142993A1
(en)
|
2002-07-01 |
2004-07-22 |
Carlo Battistini |
Inhibitors of HCV NS5B polymerase
|
US20060264389A1
(en)
|
2002-07-16 |
2006-11-23 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7323449B2
(en)
|
2002-07-24 |
2008-01-29 |
Merck & Co., Inc. |
Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US20050026853A1
(en)
|
2002-07-25 |
2005-02-03 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza D-nucleosides and uses thereof
|
ES2547002T3
(es)
|
2002-09-13 |
2015-09-30 |
Novartis Ag |
Beta-L-2' desoxinucleósidos para el tratamiento de cepas de VHB resistentes
|
AU2003287160A1
(en)
|
2002-10-15 |
2004-05-04 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
EP1576138B1
(en)
|
2002-11-15 |
2017-02-01 |
Idenix Pharmaceuticals LLC. |
2'-methyl nucleosides in combination with interferon and flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
JP5116972B2
(ja)
|
2002-12-12 |
2013-01-09 |
イデニクス(ケイマン)リミテツド |
2’−分枝ヌクレオシドの製造方法
|
JP4996241B2
(ja)
|
2003-01-14 |
2012-08-08 |
ギリアード サイエンシーズ, インコーポレイテッド |
組み合わせ抗ウイルス治療のための組成物および方法
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
WO2004080466A1
(en)
|
2003-03-07 |
2004-09-23 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
CN101415719A
(zh)
|
2003-03-20 |
2009-04-22 |
微生物化学及药品有限公司 |
生产2’-脱氧-β-L-核苷的方法
|
ATE422895T1
(de)
|
2003-04-16 |
2009-03-15 |
Bristol Myers Squibb Co |
Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
SG182849A1
(en)
|
2003-04-25 |
2012-08-30 |
Gilead Sciences Inc |
Antiviral phosphonate analogs
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
WO2004096210A1
(en)
|
2003-05-01 |
2004-11-11 |
Glaxo Group Limited |
Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
BR122018015050B1
(pt)
|
2003-05-30 |
2021-07-13 |
Gilead Pharmasset Llc |
Derivados fosfatados de nucleosídeo e composição farmacêutica dos mesmos
|
EP1644479A4
(en)
|
2003-06-16 |
2008-04-23 |
Mark W Grinstaff |
MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
CN1852915A
(zh)
|
2003-07-25 |
2006-10-25 |
艾登尼科斯(开曼)有限公司 |
治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
|
EP1660511B1
(en)
|
2003-08-27 |
2010-11-03 |
Biota Scientific Management Pty. Ltd. |
Novel tricyclic nucleosides or nucleotides as therapeutic agents
|
TW200526686A
(en)
|
2003-09-18 |
2005-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050148534A1
(en)
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
US7026339B2
(en)
|
2003-11-07 |
2006-04-11 |
Fan Yang |
Inhibitors of HCV NS5B polymerase
|
TW200528459A
(en)
|
2004-01-06 |
2005-09-01 |
Achillion Pharmaceuticals Inc |
Azabenzofuran substituted thioureas; inhibitors of viral replication
|
US20070155731A1
(en)
|
2004-01-28 |
2007-07-05 |
Gabor Butora |
Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
|
AU2005216971A1
(en)
|
2004-02-25 |
2005-09-09 |
Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Office Of Technology Transfer |
Methylation inhibitor compounds
|
GB0408995D0
(en)
|
2004-04-22 |
2004-05-26 |
Glaxo Group Ltd |
Compounds
|
CA2568379A1
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
US20060040944A1
(en)
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
CN1972696B
(zh)
|
2004-06-24 |
2010-08-11 |
默沙东公司 |
用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
|
US7217523B2
(en)
|
2004-07-02 |
2007-05-15 |
Regents Of The University Of Minnesota |
Nucleoside phosphoramidates and nucleoside phosphoramidases
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
US7871991B2
(en)
|
2004-07-27 |
2011-01-18 |
Gilead Sciences, Inc. |
Phosphonate analogs of HIV inhibitor compounds
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
ES2327252T3
(es)
|
2004-08-23 |
2009-10-27 |
F. Hoffmann-La Roche Ag |
4'-azido nucleosidos antivirales.
|
KR100847181B1
(ko)
|
2004-08-23 |
2008-07-17 |
에프. 호프만-라 로슈 아게 |
이종환 항바이러스 화합물
|
ES2725457T3
(es)
|
2004-09-14 |
2019-09-24 |
Gilead Pharmasset Llc |
Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
|
AU2005289517A1
(en)
|
2004-09-24 |
2006-04-06 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
|
CN100594903C
(zh)
|
2004-09-30 |
2010-03-24 |
泰博特克药品有限公司 |
Hcv抑制性双环嘧啶
|
WO2006063149A1
(en)
|
2004-12-09 |
2006-06-15 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
WO2006063717A2
(en)
|
2004-12-16 |
2006-06-22 |
Febit Biotech Gmbh |
Polymerase-independent analysis of the sequence of polynucleotides
|
WO2006093801A1
(en)
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
CN101142226A
(zh)
|
2005-02-28 |
2008-03-12 |
健亚生物科技公司 |
用于治疗病毒感染的三环核苷化合物
|
WO2006094347A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
WO2006100310A1
(en)
|
2005-03-25 |
2006-09-28 |
Tibotec Pharmaceuticals Ltd |
Heterobicylic inhibitors of hcv
|
WO2006116557A1
(en)
|
2005-04-25 |
2006-11-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
TW200716631A
(en)
|
2005-05-12 |
2007-05-01 |
Tibotec Pharm Ltd |
Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
TWI375560B
(en)
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
CN101263156A
(zh)
|
2005-07-25 |
2008-09-10 |
因特蒙公司 |
C型肝炎病毒复制的新颖大环抑制剂
|
CN101277682B
(zh)
|
2005-07-28 |
2015-07-29 |
Isp投资有限公司 |
无定形依发韦仑及其生产
|
JP5171624B2
(ja)
|
2005-07-29 |
2013-03-27 |
テイボテク・フアーマシユーチカルズ |
C型肝炎ウイルスの大環状阻害剤
|
WO2007014920A1
(en)
|
2005-07-29 |
2007-02-08 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
WO2007013047A2
(en)
|
2005-07-29 |
2007-02-01 |
Ranbaxy Laboratories Limited |
Water-dispersible anti-retroviral pharmaceutical compositions
|
CN101282978B
(zh)
|
2005-07-29 |
2012-07-11 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US7666834B2
(en)
|
2005-07-29 |
2010-02-23 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis C virus
|
JP2009504704A
(ja)
|
2005-08-15 |
2009-02-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
|
GB0519478D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
GB0519488D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
NZ568909A
(en)
|
2005-12-09 |
2011-10-28 |
Hoffmann La Roche |
Antiviral 4-fluoro-4-methyl nucleoside prodrugs
|
AU2006326494A1
(en)
|
2005-12-12 |
2007-06-21 |
Genelabs Technologies, Inc. |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
GB0602046D0
(en)
|
2006-02-01 |
2006-03-15 |
Smithkline Beecham Corp |
Compounds
|
WO2007092000A1
(en)
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
WO2007095269A2
(en)
|
2006-02-14 |
2007-08-23 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
KR20080085232A
(ko)
|
2006-02-17 |
2008-09-23 |
화이자 리미티드 |
Tlr7 조절제로서 3-데아자퓨린 유도체
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
JP5205370B2
(ja)
|
2006-05-25 |
2013-06-05 |
ブリストル−マイヤーズ スクイブ カンパニー |
シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤
|
EP2043613A1
(en)
|
2006-07-14 |
2009-04-08 |
Fmc Corporation |
Solid form
|
EP1881001A1
(en)
|
2006-07-20 |
2008-01-23 |
Tibotec Pharmaceuticals Ltd. |
HCV NS-3 serine protease inhibitors
|
US8912321B2
(en)
|
2006-10-10 |
2014-12-16 |
Gilead Pharmasset Llc |
Preparation of nucleosides ribofuranosyl pyrimidines
|
PL216525B1
(pl)
|
2006-10-17 |
2014-04-30 |
Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk |
5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
JP2010513484A
(ja)
|
2006-12-20 |
2010-04-30 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート
|
WO2008085508A2
(en)
|
2007-01-05 |
2008-07-17 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
GB0709791D0
(en)
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CN101108870A
(zh)
|
2007-08-03 |
2008-01-23 |
冷一欣 |
核苷磷酸酯类化合物及制备方法和应用
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
WO2009086192A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma, Inc. |
Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
US20110130440A1
(en)
|
2008-03-26 |
2011-06-02 |
Alnylam Pharmaceuticals, Inc. |
Non-natural ribonucleotides, and methods of use thereof
|
EP3042660A3
(en)
|
2008-04-15 |
2016-10-26 |
RFS Pharma, LLC. |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
AU2009329867B2
(en)
*
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CN102753563A
(zh)
*
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
WO2010080878A1
(en)
|
2009-01-07 |
2010-07-15 |
Scynexis, Inc. |
Combination of a cyclosporine derivative and nucleosides for treating hcv
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
EP2646453A1
(en)
|
2010-11-30 |
2013-10-09 |
Gilead Pharmasset LLC |
Compounds
|